October 15, 2014Open Access

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Key Points

Key points are not available for this paper at this time.

Abstract

Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Shannon L. Maude

Noelle V. Frey

Pamela A. Shaw

Journals

New England Journal of Medicine

Actions

Institutions

University of Pennsylvania

Children's Hospital of Philadelphia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study